Quick Answer
Barinthus Biotherapeutics plc. reported Total Assets of $98.17 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -38.8% in Total Assets from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $166.49 million | Q2 2021: $259.84 million | Q3 2021: $256.57 million | Q1 2022: $286.12 million | Q2 2022: $285.06 million | Q3 2022: $275.48 million | Q1 2023: $261.82 million | Q2 2023: $246.13 million | Q3 2023: $229.97 million | Q1 2024: $199.48 million | Q2 2024: $186.75 million | Q3 2024: $188.69 million | Q1 2025: $142.00 million | Q2 2025: $129.56 million | Q3 2025: $109.20 million.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Total Assets has grown by 93.8%.
- Historical annual values: Fiscal year 2025: $98.17 million | Fiscal year 2024: $160.33 million | Fiscal year 2023: $214.51 million | Fiscal year 2022: $270.21 million | Fiscal year 2021: $280.72 million | Fiscal year 2020: $50.67 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: